Dr. Nathaniel L. Peyton, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Louisville School of Medicine (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 231
Licensed in Alabama since 2022, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: University of Louisville School of Medicine
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
AL license MD.44675 (first issued 2022; active) -
Internal Medicine Physician
LA license 308623 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Grandview Medical Center Birmingham, AL
- Baptist Health Brookwood Hospital Birmingham, AL
- Shelby Baptist Medical Center Alabaster, AL
- St Vincent's Chilton Clanton, AL
Medical groups
- Gastroenterology Associates of North-Central Alabama Inc (94 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 231
- Services billed
- 7,825
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, vedolizumab, 1 mg | 8,400 | 20 |
| Injection, infliximab, excludes biosimilar, 10 mg | 1,650 | 16 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 88 | 53 |
| New patient office or other outpatient visit, 45-59 minutes | 50 | 50 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 41 | 39 |
| Established patient office or other outpatient visit, 20-29 minutes | 38 | 28 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 32 | 30 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 29 | 21 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 28 | 28 |
| Administration of chemotherapy into vein, 1 hour or less | 27 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Omeprazole Other prescribers in New Orleans, LA | 152 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in New Orleans, LA | 124 |
| Pantoprazole Sodium Other prescribers in New Orleans, LA | 70 |
| Dicyclomine Hcl Other prescribers in New Orleans, LA | 59 |
| Sucralfate Other prescribers in New Orleans, LA | 45 |
| Colestipol Hcl Other prescribers in New Orleans, LA | 34 |
| Creon (lipase/protease/amylase) Other prescribers in New Orleans, LA | 33 |
| Famotidine Other prescribers in New Orleans, LA | 26 |
| Esomeprazole Magnesium Other prescribers in New Orleans, LA | 18 |
| Peg 3350-Electrolyte (sodium chloride/nahco3/kcl/peg) | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 62 payments worth $1,067 in total to this clinician.
| AbbVie Inc. | $345 |
|---|---|
| Janssen Biotech, Inc. | $195 |
| Lilly USA, LLC | $136 |
| Genzyme Corporation | $70.00 |
| Aimmune Therapeutics, Inc. | $57.08 |
| Takeda Pharmaceuticals U.S.A., Inc. | $56.49 |
| Ardelyx, Inc. | $55.76 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.05 |
| Food and Beverage | $1,067 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.